Hansa Biopharma AB (publ) (LON:0RC7)
London
· Delayed Price · Currency is GBP · Price in SEK 25.16
+0.28 (1.13%)
At close: May 13, 2025
Hansa Biopharma AB Cash Flow Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -625.74 | -807.24 | -831.72 | -611.13 | -548.28 | -420.85 | Upgrade
|
| Depreciation & Amortization | 10.09 | 10.09 | 10.74 | 9.96 | 6.51 | 7.67 | Upgrade
|
| Other Amortization | 17.98 | 17.98 | 9.05 | 2.09 | 2.09 | - | Upgrade
|
| Stock-Based Compensation | 31.69 | 31.69 | 60.64 | 58.23 | 56.62 | 43.35 | Upgrade
|
| Other Operating Activities | -17.94 | 136.64 | -15.8 | 16.69 | -1 | 0.24 | Upgrade
|
| Change in Accounts Receivable | -66.94 | -66.94 | -35.07 | -33.25 | -9.6 | 0.41 | Upgrade
|
| Change in Accounts Payable | -49.35 | -49.35 | 24.49 | 9.12 | 28.58 | -23.9 | Upgrade
|
| Change in Other Net Operating Assets | 62.6 | 52.26 | 22.01 | 45.56 | -16.09 | 102.81 | Upgrade
|
| Operating Cash Flow | -637.61 | -674.88 | -755.65 | -502.73 | -481.17 | -290.27 | Upgrade
|
| Capital Expenditures | -0.63 | -0.12 | -0.28 | -3.33 | -2.4 | -0.29 | Upgrade
|
| Investment in Securities | - | - | - | 232.64 | - | 182.83 | Upgrade
|
| Investing Cash Flow | -0.63 | -0.12 | -0.28 | 229.31 | -2.4 | 182.53 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 736.4 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -7.5 | -7.55 | -6.89 | -4.86 | -4.67 | Upgrade
|
| Total Debt Repaid | -6.95 | -7.5 | -7.55 | -6.89 | -4.86 | -4.67 | Upgrade
|
| Net Debt Issued (Repaid) | -6.95 | -7.5 | -7.55 | 729.51 | -4.86 | -4.67 | Upgrade
|
| Issuance of Common Stock | 372.15 | 372.15 | - | 415.95 | - | 1,112 | Upgrade
|
| Other Financing Activities | -17.85 | -17.85 | - | -27.78 | - | -41.26 | Upgrade
|
| Financing Cash Flow | 347.36 | 346.81 | -7.55 | 1,118 | -4.86 | 1,066 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.39 | 1.42 | -0.64 | 0.58 | 0.4 | -0.5 | Upgrade
|
| Net Cash Flow | -291.27 | -326.78 | -764.12 | 844.84 | -488.02 | 957.67 | Upgrade
|
| Free Cash Flow | -638.24 | -675 | -755.94 | -506.06 | -483.57 | -290.57 | Upgrade
|
| Free Cash Flow Margin | -351.29% | -394.01% | -563.74% | -327.50% | -1427.38% | -4764.97% | Upgrade
|
| Free Cash Flow Per Share | -9.58 | -10.74 | -14.39 | -11.27 | -10.87 | -6.89 | Upgrade
|
| Cash Interest Paid | - | - | - | 1.17 | - | - | Upgrade
|
| Cash Income Tax Paid | 4.18 | 3.61 | 0.13 | 1.57 | 0.14 | 0.11 | Upgrade
|
| Levered Free Cash Flow | -472.9 | -541.48 | -438.91 | -282.34 | -257.8 | -196.46 | Upgrade
|
| Unlevered Free Cash Flow | -410.9 | -457.68 | -372.96 | -255.05 | -257.36 | -196.3 | Upgrade
|
| Change in Net Working Capital | 107.39 | 122.54 | -41.37 | -38.07 | -17.04 | -18.65 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.